Lanabecestat

Generic Name: Lanabecestat

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₂₈N_₄O

CAS Number: 1383982-64-6

Unique Ingredient Identifier: X8SPJ492VF

Background: Lanabecestat is under investigation in clinical trial NCT03499041 (A Study of LY3314814 in Participants With Liver Impairment).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A Study of Lanabecestat in Participants With Severe Kidney Impairment Compared to Healthy Participants

Phase 1

Withdrawn

Conditions: Renal Insufficiency

Interventions: Drug: Lanabecestat
Drug: Iohexol

First Posted Date: 2018-06-04

Last Posted Date: 2018-06-28

Lead Sponsor: Eli Lilly and Company

Registration Number: NCT03545087

Locations: 🇺🇸
Orange County Research Center, Tustin, California, United States
🇺🇸
Clinical Pharmacology of Miami, Miami, Florida, United States
🇺🇸
Orlando Clinical Research Ctr., Orlando, Florida, United States

A Study of Lanabecestat in Healthy Female Participants Taking Oral Contraceptive

Phase 1

Withdrawn

Conditions: Healthy

Interventions: Drug: Oral Contraceptive
Drug: Lanabecestat

First Posted Date: 2018-04-24

Last Posted Date: 2018-06-28

Lead Sponsor: Eli Lilly and Company

Registration Number: NCT03506399

Locations: 🇸🇬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Singapore, Singapore

A Study of Lanabecestat (LY3314814) in Healthy Participants When Taken With Rosuvastatin

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Rosuvastatin
Drug: Lanabecestat

First Posted Date: 2017-01-12

Last Posted Date: 2019-11-01

Lead Sponsor: AstraZeneca

Target Recruit Count: 42

Registration Number: NCT03019549

Locations: 🇺🇸
Covance Clinical Research Inc, Daytona Beach, Florida, United States

A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia

Phase 3

Terminated

Conditions: Alzheimer's Disease

Interventions: Drug: Lanabecestat

First Posted Date: 2016-11-23

Last Posted Date: 2019-12-03

Lead Sponsor: AstraZeneca

Target Recruit Count: 421

Registration Number: NCT02972658

Locations: 🇺🇸
Brain Matters Research, Delray Beach, Florida, United States
🇺🇸
IMIC, Inc., Palmetto Bay, Florida, United States
🇺🇸
Suncoast Neuroscience Associates, Saint Petersburg, Florida, United States

and more 126 locations

A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia

Phase 3

Terminated

Conditions: Alzheimer's Disease

Interventions: Drug: Lanabecestat
Drug: Placebo

First Posted Date: 2016-05-26

Last Posted Date: 2019-12-03

Lead Sponsor: AstraZeneca

Target Recruit Count: 1722

Registration Number: NCT02783573

Locations: 🇺🇸
Maine Neurology, Scarborough, Maine, United States
🇺🇸
Eastern Maine Medical Center, Bangor, Maine, United States
🇺🇸
Atlanta Center of Medical Research, Atlanta, Georgia, United States

and more 254 locations

A Study of Lanabecestat (LY3314814) in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Lanabecestat

First Posted Date: 2016-01-26

Last Posted Date: 2019-11-01

Lead Sponsor: AstraZeneca

Target Recruit Count: 18

Registration Number: NCT02663128

A Drug-drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Lanabecestat
Drug: Dabigatran etexilate

First Posted Date: 2015-10-05

Last Posted Date: 2019-11-01

Lead Sponsor: AstraZeneca

Target Recruit Count: 60

Registration Number: NCT02568397

Locations: 🇺🇸
Covance, Dallas, Texas, United States

A Drug Interaction Study of Lanabecestat (LY3314814) and Warfarin in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Warfarin
Drug: Lanabecestat

First Posted Date: 2015-09-04

Last Posted Date: 2019-11-04

Lead Sponsor: AstraZeneca

Target Recruit Count: 15

Registration Number: NCT02540668

Locations: 🇺🇸
Covance Clinical Research Inc, Evansville, Indiana, United States

A Drug-Drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Lanabecestat
Drug: Donepezil
Drug: Simvastatin
Drug: Midazolam

First Posted Date: 2015-04-02

Last Posted Date: 2019-11-04

Lead Sponsor: AstraZeneca

Target Recruit Count: 82

Registration Number: NCT02406261

Locations: 🇺🇸
Covance Inc, Dallas, Texas, United States

An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease

Phase 2

Terminated

Conditions: Alzheimer´s Disease

Interventions: Drug: Placebo
Drug: Lanabecestat

First Posted Date: 2014-09-22

Last Posted Date: 2019-12-03

Lead Sponsor: AstraZeneca

Target Recruit Count: 2218

Registration Number: NCT02245737

Locations: 🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇨🇦
Q&T Research Sherbrooke Inc, Sherbrooke, Quebec, Canada
🇺🇸
Banner Sun Health Research Institute, Sun City, Arizona, United States

and more 246 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy